Cipla launches Spirofy for early diagnosis for COPD

Cipla will undertake training of physicians in the interpretation of spirometry results. Spirometry is the gold standard for COPD diagnosis, however owing to the bulky size, complex functionality, need for regular maintenance are some reasons that impacted the widespread acceptance of conventional spirometers by medical practitioners. This resulted in underdiagnosis or misdiagnosis of COPD cases in India.

Currently, COPD remains the 2nd most common cause of death in India after heart diseases, where India alone bears 32% of the global COPD burden.

Commenting on the launch, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, "Cipla has been steadfastly focused on addressing the world's growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy launch aims to help doctors across the country to improve lives of patients through accurate and affordable diagnosis."